Search | Clinical Trials Finder

Conditions: Chronic Severe Plaque-type Psoriasis
Interventions: Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Ankylosing Spondylitis
Interventions: Placebo, GP2017 (adalimumab biosimilar), AIN457 150 mg; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 19
States / cities: Mesa, Arizona • Escondido, California • La Mesa, California + 16 more

Conditions: Rheumatoid Arthritis
Interventions: Secukinumab (AIN457), Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 25
States / cities: Peoria, Arizona • Santa Monica, California • Upland, California + 20 more

Conditions: Uveitis
Interventions: AIN457, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 5
States / cities: Beverly Hills, California • Cambridge, Massachusetts • Slingerlands, New York + 2 more

Conditions: Chronic Scalp Psoriasis
Interventions: Secukinumab 300 mg, Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 17
States / cities: Sacramento, California • Aurora, Colorado • Trumbull, Connecticut + 13 more

Conditions: Psoriatic Arthritis
Interventions: Secukinumab (AIN457), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 21
States / cities: Peoria, Arizona • Aventura, Florida • Palm Harbor, Florida + 17 more

Conditions: Plaque-type Psoriasis
Interventions: Placebo, Secukinumab 150mg, Secukinumab 300mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Oceanside, California + 8 more

Conditions: Plaque Psoriasis
Interventions: Placebo 2 mL auto-injector, Placebo 1 mL prefilled syringe, Secukinumab 2 mL auto-injector, Secukinumab 1 mL prefilled syringe; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: Miami, Florida • Marietta, Georgia • Saint Joseph, Missouri + 5 more

Conditions: Psoriasis
Interventions: Placebo, Secukinumab 2 mL form, Secukinumab 1 mL form; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Phoenix, Arizona • Fountain Valley, California • Fremont, California + 11 more

Conditions: Arthritis, Psoriatic
Interventions: Secukinumab, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 19
States / cities: Mesa, Arizona • Upland, California • Denver, Colorado + 15 more

Conditions: Moderate to Severe Nail Psoriasis
Interventions: Secukinumab, Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 9
States / cities: Birmingham, Alabama • Phoenix, Arizona • Skokie, Illinois + 6 more

Conditions: Hidradenitis Suppurativa
Interventions: secukinumab; Biological
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Plaque-type Psoriasis
Interventions: AIN457, AIN457A, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 29
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Pasadena, California + 25 more

Conditions: Spondylitis, Ankylosing
Interventions: Secukinumab, Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Anniston, Alabama • Upland, California • Aventura, Florida + 9 more

Conditions: Psoriatic Arthritis
Interventions: AIN457 (secukinumab), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Beverly Hills, California • Los Angeles, California • Wheaton, Maryland + 1 more

Conditions: Plaque-type Psoriasis
Interventions: secukinumab 150mg, secukinumab 10mg/kg i.v. regimen; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Jacksonville, Florida • West Palm Beach, Florida • Boston, Massachusetts + 3 more

Conditions: Psoriatic Arthritis
Interventions: Secukinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 22
States / cities: Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 18 more

Conditions: Chronic Plaque-type Psoriasis
Interventions: Skin biopsies; Procedure
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: New Orleans, Louisiana • East Windsor, New Jersey • Philadelphia, Pennsylvania + 1 more

Conditions: Moderate to Severe Palmoplantar Psoriasis
Interventions: secukinumab 150 mg, secukinumab 300 mg, Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: Birmingham, Alabama • Phoenix, Arizona • Indianapolis, Indiana + 5 more

Conditions: Ankylosing Spondylitis
Interventions: 150 mg open-label secukinumab, 150 mg double-blinded secukinumab, 300 mg double-blinded secukinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 65
States / cities: Jonesboro, Arkansas • Fullerton, California • Loma Linda, California + 60 more

Conditions: Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
Interventions: Secukinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 100 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Boise, Idaho • Cincinnati, Ohio • Portland, Oregon

Conditions: Behcet Disease
Interventions: AIN457, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Baltimore, Maryland • Arlington, Texas • Houston, Texas

Conditions: Autoimmunity, Inflammation
Interventions: Secukinumab s.c. injection; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 100 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 28
States / cities: Fullerton, California • La Mesa, California • San Leandro, California + 25 more

Conditions: Spondylitis, Ankylosing
Interventions: Secukinumab, Placebo secukinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 14
States / cities: Mobile, Alabama • Mesa, Arizona • Peoria, Arizona + 11 more

Search by objective public record fields.

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)

Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.

Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis

Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis

Study of Secukinumab With 2 mL Pre-filled Syringes

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis

Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis

Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis

An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

Phase III Study in Refractory Behcet's Disease

Secukinumab Open Label Roll-over Extension Protocol

16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients